Reset filter
Trefwoorden
Pharmacotherapy ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

187 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

26672_Common Data Elements Myeloid Leukemia (MDS AML CML) - Global Disease Course

- 20-09-21 - 13 Formulieren, 3 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Global Disease Course, Red Cell Transfusion, Platelet Cell Transfusion
Common Data Elements Myeloid Leukemia (MDS, AML, CML) for use in clinical routine and clinical trial documentation. https://www.ncbi.nlm.nih.gov/pubmed/27577388

Physical Examination/Follow up

3 Itemgroepen 14 Data-elementen

Administrative/Demographic Details

1 Itemgroep 11 Data-elementen

Medical History

3 Itemgroepen 9 Data-elementen

Lab: Cytology/Cytogenetics/Cytochemistry

1 Itemgroep 29 Data-elementen

Lab: Immunophenotyping

1 Itemgroep 17 Data-elementen

Lab: Molecular Genetics

1 Itemgroep 27 Data-elementen

Study SHIP-NEXT_metadata_20240913_NEXT|NEXT0|PHA - x0.pha_quest

- 08-10-24 - 4 Formulieren, 1 Itemgroep, 6 Data-elementen, 2 Talen
Itemgroep: x0.pha_quest
Item catalog SHIP-NEXT part 8

x0.pha_ident

1 Itemgroep 20 Data-elementen

x0.pha_take

1 Itemgroep 7 Data-elementen

x0.pha_odm

1 Itemgroep 5 Data-elementen

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Sputum collection

- 27-09-21 - 1 Formulier, 7 Itemgroepen, 24 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Dosing date and time, Sputum induction, Sputum sample quality, Sputum sample preparation and hemacytometry, Sample collection summary, Sputum slide results
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the Sputum collection form. It has to be filled in for V2b, V5 and if requiered for logs/ repeats. This document can be filled in as often as necessary for logs/ repeats.

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Logs and Repeats

- 27-09-21 - 1 Formulier, 4 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Administrative Data, Date of visit/assessment, AE/Concomitant medication/Repeat an assessment check question, Liver event
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the Logs and Repeats form.

ATC A - Alimentary Tract and Metabolism

- 20-09-21 - 1 Formulier, 1 Itemgroep, 1 Data-element, 2 Talen
Itemgroep: Alimentary Tract and Metabolism
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC Codes: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

Eligibility HOMe aFers 1 NCT02905539

- 20-09-21 - 1 Formulier, 4 Itemgroepen, 36 Data-elementen, 2 Talen
Itemgroepen: Inclusion criteria, Exclusion criteria, Result of eligibility criteria verification, Administrative data
Eligibility form Prüfung der Eignung zur Studienteilnahme NCT02905539 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Quelle: Prof. Dr. med. Gunnar Heine Universitätsklinikum des Saarlandes

Multiple sclerosis studies NCT02461069 NCT02419378 - Baseline 1st cycle Trial Medication Multiple Sclerosis ALAIN01 NCT02419378

- 20-09-21 - 18 Formulieren, 2 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Medication, Trial Medication RQG
Screening, Baseline and Visit 1 CRFs of DIMAT-MS and ALAIN studies for semantic analysis of Multiple Sclerosis study documentation. Provided by Prof. Dr. Luisa Klotz of the Department of Neurology of the University Hospital Muenster.

Baseline: Repitition of Assessments: MRI Multiple Sclerosis ALAIN01 NCT02419378

1 Itemgroep 15 Data-elementen

Baseline: MRI Multiple Sclerosis ALAIN01 NCT02419378

1 Itemgroep 15 Data-elementen

Baseline: CSF Multiple Sclerosis ALAIN01 NCT02419378

1 Itemgroep 32 Data-elementen

Visit 1 (Screening) Part 2/2, Lab; Medical Examination, DIMAT-MS, Relapsing Remitting Multiple Sclerosis NCT02461069

7 Itemgroepen 40 Data-elementen

Pharmacokinetics

- 20-09-21 - 1 Formulier, 1 Itemgroep, 23 Data-elementen, 1 Taal
Itemgroep: Pharmacokinetics
Record detailed information about the collection of biological samples for analysis of the presence and quantity of the study agent and/or its metabolites. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AD257392-F827-EFBD-E040-BB89AD434E1E

Medication Form Melanoma (NCT01274338)

- 20-09-21 - 1 Formulier, 6 Itemgroepen, 35 Data-elementen, 1 Taal
Itemgroepen: Header, On Treatment Reporting Period, OFF TREATMENT, Corticosteroid Medication, Immunosuppressant Medication, Hormonal Replacement Therapy Medication
E1609 Corticosteroid/Immunosuppressant/Hormone Replacement Medication Form Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1F0BB2E-39FF-B3FA-E040-BB89AD430140

ATC J - Antiinfectives for systemic use

- 20-09-21 - 1 Formulier, 1 Itemgroep, 1 Data-element, 2 Talen
Itemgroep: Antiinfectives for systemic use
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC-Index: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

ATC R - Respiratory System

- 20-09-21 - 1 Formulier, 1 Itemgroep, 1 Data-element, 2 Talen
Itemgroep: Respiratory System
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC-Index: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

ATC C - Cardiovascular System

- 20-09-21 - 1 Formulier, 1 Itemgroep, 1 Data-element, 2 Talen
Itemgroep: Cardiovascular System
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC Index: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial